Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation

Inclusion criteria

• Male or female of nonchildbearing potential.
• Healthy subjects.

Exclusion criteria

• Evidence of coagulation disturbances, or disposition for thrombo-embolic events
• Liver function tests more than 1.2 times the upper normal limits
• Participants with thyroid disorders as evidenced by assessment of TSH levels outside the normal reference range at screening.
• Prior history of thromboembolic complications including those in first degree relatives.
• Glomerular filtration rate (GFR) is lower than estimated GFR 62 mL/min/1.73 m2 using the Modification of Diet in Renal Disease Study equation.
• Anaphylactic or systemic reactions to human plasma, plasma products, or blood products.
• History of hypersensitivity to active or inactive excipients of VKA
• Gastrointestinal disease that may impair VKA absorption..
• Participation in another clinical study <30 days prior to study entry.
• Any clinically significant history of or current clinically significant disease or disorder as judged by the Investigator.
• Positive nasopharyngeal PCR test for SARS-CoV-2 on Day -11 or Day -1.
• Positive pregnancy test at screening, Day -11, or Day -1.